Occudo Quantitative Strategies LP Makes New Investment in Myomo, Inc. (NYSEAMERICAN:MYO)

Occudo Quantitative Strategies LP purchased a new position in shares of Myomo, Inc. (NYSEAMERICAN:MYO) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 19,879 shares of the company’s stock, valued at approximately $128,000. Occudo Quantitative Strategies LP owned 0.07% of Myomo as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of MYO. Barclays PLC purchased a new position in shares of Myomo in the 3rd quarter valued at $36,000. BNP Paribas Financial Markets purchased a new position in shares of Myomo in the 4th quarter valued at $64,000. Walleye Capital LLC purchased a new position in shares of Myomo in the 4th quarter valued at $66,000. Schonfeld Strategic Advisors LLC purchased a new position in shares of Myomo in the 4th quarter valued at $95,000. Finally, Jefferies Financial Group Inc. purchased a new position in shares of Myomo in the 4th quarter valued at $101,000. Hedge funds and other institutional investors own 44.99% of the company’s stock.

Myomo Price Performance

Myomo stock opened at $3.57 on Friday. Myomo, Inc. has a 12-month low of $2.76 and a 12-month high of $7.17. The stock has a market cap of $107.99 million, a P/E ratio of -15.52 and a beta of 1.68. The business’s fifty day moving average price is $4.59.

Insider Transactions at Myomo

In related news, CEO Paul R. Gudonis bought 30,000 shares of the company’s stock in a transaction dated Thursday, May 15th. The stock was bought at an average price of $3.22 per share, with a total value of $96,600.00. Following the transaction, the chief executive officer now owns 1,051,671 shares of the company’s stock, valued at approximately $3,386,380.62. This trade represents a 2.94% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Thomas F. Kirk bought 7,400 shares of the company’s stock in a transaction dated Thursday, March 13th. The stock was bought at an average cost of $5.00 per share, with a total value of $37,000.00. Following the transaction, the director now directly owns 255,933 shares in the company, valued at approximately $1,279,665. The trade was a 2.98% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 126,167 shares of company stock valued at $427,093. Insiders own 4.54% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on MYO shares. Ascendiant Capital Markets raised their target price on shares of Myomo from $9.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, March 17th. Alliance Global Partners reaffirmed a “buy” rating on shares of Myomo in a research note on Tuesday, March 11th. Craig Hallum dropped their price target on shares of Myomo from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Thursday, May 8th. Finally, HC Wainwright lifted their price target on shares of Myomo from $7.50 to $9.50 and gave the stock a “buy” rating in a research note on Wednesday, March 12th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $9.50.

About Myomo

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.